Catherine Sabatos-Peyton

Author

Novartis (United States)

Also Known As

Catherine A Sabatos-Peyton, Catherine A. Sabatos-Peyton, Catherine A. Sabatos‐Peyton, Catherine Sabatos-Peyton

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Novartis (United States)Novartis (Switzerland)National Cancer Centre Singapore University of Bristol The University of Texas MD Anderson Cancer Center

About

Catherine Sabatos-Peyton is an author at Novartis (United States) specializing in medicine, immunology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	283
2	Cell Biology	5	5	171
3	Health Sciences	1	1	17
4	Allergy	1	1	114
5	Cellular Physiology	1	1	18

Catherine Sabatos-Peyton

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Clinical Cancer Research	2021	335
Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy Bronwen R. Burton, Graham J. Britton, Hai Fang, Nature Communications	2014	182
Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10–secreting Th1 cells Leona Gabryšová, Kirsty Nicolson, Heather B. Streeter, The Journal of Experimental Medicine	2009	150
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies Patrick Schöffski, Daniel Shao-Weng Tan, Miguel Martín, Journal for ImmunoTherapy of Cancer	2022	147
Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy Simone Bonazzi, Eva d’Hennezel, Rohan E. J. Beckwith, Cell chemical biology	2023	135
Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma Weiqing Jing, Jill A. Gershan, James J. Weber, Journal for ImmunoTherapy of Cancer	2015	117
T‐bet, a Th1 transcription factor regulates the expression of Tim‐3 Ana C. Anderson, Graham M. Lord, Valérie Dardalhon, European Journal of Immunology Th1 Transcription FactorT-regulatory CellImmunologyImmune RegulationImmunologic Mechanism	2010	114
Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy Catherine Sabatos-Peyton, James Nevin, Ansgar Brock, OncoImmunology	2017	106
Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies. David S. Hong, Patrick Schöffski, Aitana Calvo, Journal of Clinical Oncology Phase I/ii StudyImmunologyPathologyBrain Tumor EdemaPharmacotherapy	2018	69
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, Blood	2020	68

Page 1